
NYSEHealthcareMedical - Diagnostics & Research
أحدث البيانات المتاحة
45.38 US$
+0.85 US$ · +1.91%
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
الإغلاق السابق
45.38 US$
+0.85 US$ · +1.91%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
نطاق اليوم
السعر الحالي 45.38 US$
نطاق 52 أسبوعًا
السعر الحالي 45.38 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
94
قيمة جذابة جدًا
المشاعر
63
صعودي
المخاطر
41
مخاطر أعلى من المعتاد
الزخم
56
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
نطاق اليوم
السعر الحالي 45.38 US$
نطاق 52 أسبوعًا
السعر الحالي 45.38 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 2.09 مليار USD | 1.98 مليار USD | 1.97 مليار USD | 2.14 مليار USD | 2.25 مليار USD |
| تكلفة البضاعة المباعة | 798.5 مليون USD | 1.01 مليار USD | 731.62 مليون USD | 756.96 مليون USD | 800.84 مليون USD |
| الربح الإجمالي | 1.29 مليار USD | 967.35 مليون USD | 1.23 مليار USD | 1.38 مليار USD | 1.45 مليار USD |
| البحث والتطوير | 187.52 مليون USD | 193.49 مليون USD | 198.51 مليون USD | 189.86 مليون USD | 189.96 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 583.67 مليون USD | 564.36 مليون USD | 579.17 مليون USD | 603.95 مليون USD | 584.47 مليون USD |
| نفقات التشغيل | 771.19 مليون USD | 869.64 مليون USD | 823.75 مليون USD | 853.1 مليون USD | 820.74 مليون USD |
| دخل الفوائد | 64.32 مليون USD | 68.02 مليون USD | 78.99 مليون USD | 32.76 مليون USD | 9.56 مليون USD |
| مصاريف الفوائد | 33.26 مليون USD | 43.84 مليون USD | 53.41 مليون USD | 58.36 مليون USD | 54.48 مليون USD |
| الاستهلاك والإطفاء | 193.75 مليون USD | 203.27 مليون USD | 205.34 مليون USD | 208.4 مليون USD | 214.93 مليون USD |
| الدخل التشغيلي | 520.31 مليون USD | 97.71 مليون USD | 409.94 مليون USD | 531.46 مليون USD | 630.08 مليون USD |
| صافي الدخل | 424.88 مليون USD | 83.59 مليون USD | 341.3 مليون USD | 423.21 مليون USD | 512.6 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
43.01 US$
انخفاض محتمل بنسبة 5.22%صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Russell Mid-Cap ETFIWR38.12 مليون0.07%56.76 مليار USD0.18%109.82 US$+0.87%
iShares Russell 1000 Value ETFIWD20.41 مليون0.02%82.95 مليار USD0.18%253.54 US$+0.61%
First Trust Health Care AlphaDEX FundFXH15.43 مليون1.39%1.11 مليار USD0.61%130.15 US$+1.37%
iShares Russell Mid-Cap Value ETFIWS13.93 مليون0.09%15.31 مليار USD0.23%164.89 US$+0.61%
Invesco Biotechnology & Genome ETFPBE12.17 مليون2.88%421.57 مليون USD0.59%97.065 US$+2.98%
iShares Systematic Alternatives Active ETFIALT6.33 مليون0.08%7.56 مليار USD0.99%30.09 US$+0.60%
iShares Russell 1000 ETFIWB6.32 مليون0.01%49.62 مليار USD0.15%425.33 US$+0.67%
iShares U.S. Healthcare ETFIYH5.97 مليون0.15%4.18 مليار USD0.37%72.14 US$+1.72%
iShares Russell Mid-Cap ETFIWR
iShares Russell 1000 Value ETFIWD
First Trust Health Care AlphaDEX FundFXH
iShares Russell Mid-Cap Value ETFIWS
Invesco Biotechnology & Genome ETFPBE
iShares Systematic Alternatives Active ETFIALT
iShares Russell 1000 ETFIWB
iShares U.S. Healthcare ETFIYHالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.